{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:38:07Z","timestamp":1769236687365,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cutaneous angiosarcoma (cAS) is an aggressive vascular tumor that originates from vascular or lymphatic epithelial cells. To date, the cAS literature has been limited in a small number with single-center experiences or reports due to its rarity and the optimal treatment strategy is still in dispute. This study aimed to conduct a systematic review and compare the effect of available treatments retrieved from observational studies and Surveillance, Epidemiology, and End Results (SEER) program.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The authors performed a systematic review in the PubMed, Embase and MEDLINE database identifying the researches assessing the treatment for cAS patients. Clinical and treatment information of patients who had been diagnosed with a primary cAS were also obtained from the SEER program.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-two studies were eligible but only 5 of which with 276 patients were included in meta-analysis since the unclear or unavailable information. The risk ratio of 5-year death for surgery, surgery with radiotherapy and surgery with chemotherapy were 0.84, 0.96, and 0.69. Meanwhile, in SEER database, there are 291 metastatic and 437 localized patients with cAS. The localized patients receiving surgery showed a significantly worse overall survival result when compared with the surgery combined with RT: hazard ratio: 1.6, 95% confidential interval: 1.05, 2.42, P = 0.03.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, our study provided a detailed picture of the effectiveness of present treatments for localized and metastatic cAS patients. The CT could be inappropriate in localized patients. For metastatic patients, the surgery combined RT was recommended compared with surgery alone since its enhanced OS prognosis. Yet, more novel-designed clinical trials with specific targeted populations and rigorous conducting are needed for a solid conclusion on which would be a better treatment strategy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.627113","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T08:56:44Z","timestamp":1614243404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The Effectiveness of Different Treatment Modalities of Cutaneous Angiosarcoma: Results From Meta-Analysis and Observational Data From SEER Database"],"prefix":"10.3389","volume":"11","author":[{"given":"Siwei","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.04.010","article-title":"Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease","volume":"138","author":"Weidema","year":"2019","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3820","article-title":"Diffuse alveolar hemorrhage due to metastatic angiosarcoma of the lung: A case report","volume":"10","author":"Pan","year":"2015","journal-title":"Oncol Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.07.005","article-title":"Angiosarcomas and other sarcomas of endothelial origin","volume":"27","author":"Cioffi","year":"2013","journal-title":"Hematol\/Oncol Clinics North America"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"key":"B5","article-title":"Angiosarcoma: a review of diagnosis and current treatment","volume":"9","author":"Cao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2010.07.012","article-title":"Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007","volume":"15","author":"Albores-Saavedra","year":"2011","journal-title":"Ann Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-018-0978-3","article-title":"Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases","volume":"13","author":"Lee","year":"2019","journal-title":"Head Neck Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-018-0531-3","article-title":"Current and Future Directions for Angiosarcoma Therapy","volume":"19","author":"Florou","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000427","article-title":"Cutaneous angiosarcoma: update on biology and latest treatment","volume":"30","author":"Ishida","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/321896","article-title":"Surgical Treatment and Prognosis of Angiosarcoma of the Scalp: A Retrospective Analysis of 14 Patients in a Single Institution","volume":"2015","author":"Choi","year":"2015","journal-title":"BioMed Res Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.02.246","article-title":"Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face -a retrospective study of 38 untreated cases in the Japanese population","volume":"44","author":"Oashi","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12346","article-title":"Radiation Therapy for Angiosarcoma of the Scalp: Total Scalp Irradiation and Local Irradiation","volume":"38","author":"Hata","year":"2018","journal-title":"Anticancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2015.01005","article-title":"Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel","volume":"9","author":"Kajihara","year":"2015","journal-title":"Drug Discovery Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.01.015","article-title":"PDK1 is a potential therapeutic target against angiosarcoma cells","volume":"78","author":"Wada","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40425-017-0263-0","article-title":"Angiosarcoma treated successfully with anti-PD-1 therapy - a case report","volume":"5","author":"Sindhu","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B17","unstructured":"2020"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B20","first-page":"iii","volume-title":"Evaluating non-randomised intervention studies. Health technology assessment","author":"Deeks","year":"2003"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res ed)"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"B23","volume-title":"dmetar: Companion R Package For The Guide \u201cDoing Meta-Analysis in R\u201d. R package version 0.0. 9000","author":"Harrer","year":"2019"},{"key":"B24","volume-title":"rjags: Bayesian graphical models using MCMC","author":"Plummer","year":"2016"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"B26","unstructured":"survminer: Drawing Survival Curves using \u2018ggplot2\u2019\n            KassambaraA\n            KosinskiM\n            BiecekP\n          2020"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3083-6","article-title":"Cutaneous angiosarcoma: a single-institution experience","volume":"20","author":"Perez","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B28","volume-title":"Prognosis of cutaneous angiosarcoma in Japan: A statistical study of sixty-nine cases","author":"Matsumoto","year":"1986"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870301)59:5<1046::aid-cncr2820590533>3.0.co;2-6","article-title":"Angiosarcoma of the face and scalp, prognosis and treatment","volume":"59","author":"Holden","year":"1987","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10886","article-title":"Clinical outcomes in primary scalp angiosarcoma","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198907000-00011","article-title":"Cutaneous angiosarcoma of the face and scalp","volume":"84","author":"Barttelbort","year":"1989","journal-title":"Plast Reconstr Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24554","article-title":"Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis","volume":"39","author":"Shin","year":"2017","journal-title":"Head Neck"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14479","article-title":"Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma","volume":"32","author":"Trofymenko","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00046","article-title":"Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor","volume":"8","author":"Fujisawa","year":"2018","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.763","article-title":"Cutaneous Angiosarcoma of Head and Neck - A Single-Centre Analysis","volume":"7","author":"Wollina","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21513","article-title":"Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp","volume":"33","author":"Guadagnolo","year":"2011","journal-title":"Head Neck"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13110","article-title":"Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study","volume":"171","author":"Fujisawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr138","article-title":"Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome","volume":"23","author":"Penel","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204601","article-title":"Cutaneous angiosarcoma: a current update","volume":"70","author":"Shustef","year":"2017","journal-title":"J Clin Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet (London England)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet (London England)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12032-016-0831-z","article-title":"Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma","volume":"33","author":"Ogata","year":"2016","journal-title":"Med Oncol (Northwood London England)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"19042","DOI":"10.1111\/bjd.19042","article-title":"The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study","volume":"20","author":"Fujisawa","year":"2020","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.01.006","article-title":"Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group","volume":"51","author":"Le Cesne","year":"2015","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"New Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2015.499","article-title":"Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma","volume":"9","author":"Banavali","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2554","article-title":"Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated \u03b2-Blockade","volume":"151","author":"Chow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","article-title":"Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study","volume":"6","author":"Pasquier","year":"2016","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627113\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T08:57:01Z","timestamp":1614243421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627113\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":52,"alternative-id":["10.3389\/fonc.2021.627113"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.627113","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"627113"}}